Kyle Koeppler, COO, Luminus Diagnostics
The novel COVID-19 (coronavirus) outbreak is one of the biggest pandemics that the world has fought in recent times. While international medical organizations and governments are leaving no stone unturned to contain the deadly virus, the fear of getting infected is still looming large among the people and the medical staff attending them. In such a scenario, an accurate, actionable, and rapid diagnostics and testing solution is the first major step in combating such an infectious disease. Georgia-based firm Luminus Diagnostics has created a niche for itself in the healthcare space with its sheer commitment to excellence in diagnostics and testing. Moving beyond a boutique toxicology company, Luminus today stands as a fullservice specialty lab with an integrated technology platform designed to streamline and enhance patient insights, test ordering, and practice performance.
Luminus conducts rapid molecular testing to deliver faster and actionable testing results, which helps in early disease identification and treatment support as well as cost-savings through reduced hospitalization rate. The company utilizes certified practices and the most advanced technology to deliver high patient satisfaction. “We believe in continual process improvement strategies and rely on technology enhancements to assist with our processes,” says Kyle Koeppler, the COO of Luminus.
With the rampant evolution of diagnostics, Luminus has transformed into an organization that is nimble, malleable, and flexible. The company has pioneered new testing platforms to deliver information in a clear and concise manner, allowing administrators and staff to steer clear of the barriers related to test ordering and other processes.
Luminus conducts rapid molecular testing to deliver faster and actionable testing results, which helps in early disease identification and treatment support as well as cost-savings through reduced hospitalization rate
By integrating technology with diagnostics, team Luminus interprets the results of the molecular tests and shares the findings with the healthcare professionals for faster decision making. “Our teams, especially those in lab operations and Sales and Client Support, use multiple means to provide continuous education to our clients for maximum outcomes,” explains Koeppler. “There’s always more we can do and focus on improving daily.”
Over the years, Luminus has continually been investing in its internal resources and partners who are experts in genetics, infectious diseases, and technology. The continued investment is to stay ahead of the curve and deliver actionable results to its diverse end-users. This combination of strategy, technology, and talent helps Luminus in its mission to provide valuable insights to the end-users, and thereby, impact the entire healthcare ecosystem. “For example, when a physician submits a PCR based infectious disease test, we’re able to identify the pathogen; viral, bacterial, fungal very accurately while identifying the antibiotic resistance genes of the pathogen, within 24 hours of receipt at the lab, giving the physician much needed guidance quickly to treat the patient most effectively,” says Koeppler.
What gives Luminus a competitive edge over its peers is the combined effort of different teams to cocreate new technologies. The company continues to strengthen its capabilities by working on its core competencies, filling the capability gaps, enhancing service quality, and continuing to invest in its people. Currently, Luminus operates in over 32 states in the US and is at the precipice of many exciting opportunities. Luminus aims to have its presence in over 45 states by the fourthquarter of 2020. Besides, the firm intends to expand its payer network. Staying true to its mission statement, the company continues to propel itself forward.